Clinical trial
Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00253578 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00253578 |
|---|---|
| Title | Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | A Phase II Trial of BAY 43-9006 (Sorafenib) (NSC-724772) in Patients With Relapsing or Resistant Multiple Myeloma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Refractory Multiple Myeloma |
| Intervention type | Drug, Other |
| Interventions | sorafenib tosylate, laboratory biomarker analysis |
| Enrollment | 40 |
| Start date | Mar 1, 2006 |
| Primary completion | Nov 1, 2007 |
| First posted | Nov 15, 2005 |
| Last update posted | Jan 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: